Next-generation antibody therapeutics represent a class of advanced antibody-based drugs characterized by enhanced structures, functionalities, and therapeutic potential beyond traditional monoclonal antibodies. These therapeutics are employed to address severe medical conditions, including cancer, infectious infections, and immunological disorders.
The main types of antibodies in next-generation antibody therapeutics include monoclonal antibodies, polyclonal antibodies, biospecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-produced proteins designed to bind to specific targets, such as antigens on the surface of cancer cells. These therapeutics find applications across various therapeutic areas, including oncology, autoimmune diseases, infectious diseases, neurodegenerative disorders, and others. They are utilized in hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other relevant entities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The next-generation antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides next-generation antibody therapeutics market statistics, including next-generation antibody therapeutics industry global market size, regional shares, competitors with a next-generation antibody therapeutics market share, detailed next-generation antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation antibody therapeutics industry. This next-generation antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $6.82 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to monoclonal antibody success, rising prevalence of chronic diseases, approval of antibody-drug conjugates, growth of immunotherapy, gene therapy and antibodies.
The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $11.34 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to biosimilar development, bispecific antibodies development, nanobody development, patient-centric approaches, immunomodulatory antibodies, expanded applications in autoimmune diseases, continuous manufacturing. Major trends in the forecast period include advancements in antibody engineering, digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, real-world evidence in antibody development.
The forecast of 10.7% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of bispecific antibody drugs sourced from Ireland and Denmark, thereby slowing treatment for autoimmune diseases and elevating specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated rise in the prevalence of chronic diseases is poised to drive the growth of the next-generation antibody therapeutics market. Chronic diseases, enduring for a year or more, necessitate continuous medical care and often restrict daily activities. Next-generation antibody therapeutics play a pivotal role in offering targeted care for individuals with chronic illnesses, contributing to improved patient outcomes. As per projections from the National Center for Biotechnology Information (NCBI) in January 2023, the number of individuals aged 50 and older with at least one chronic illness is expected to surge by 99.5% by the year 2050, reaching 142.66 million. This underscores the pivotal role of next-generation antibody therapeutics in addressing the escalating prevalence of chronic diseases.
The increasing demand for pharmaceutical companies is set to propel the growth of the next-generation antibody therapeutics market. With a focus on drug discovery, development, production, and marketing, the pharmaceutical industry plays a crucial role in healthcare. Next-generation antibody therapeutics offer advantages such as improved targeting precision, reduced side effects, personalized medicine, extended half-life, dosage interval innovations, multifunctional antibodies, and optimized manufacturing processes. In June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from 2021. This underscores the growing demand for pharmaceutical companies, thereby driving the next-generation antibody therapeutics market.
Technological advancements are a significant trend gaining traction in the next-generation antibody therapeutics market. Major companies in this field are focusing on developing innovations like proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to enhance protein identification and characterization, resulting in more targeted and effective treatments. These advancements are intended to improve therapeutic profiles, reduce costs, and tackle complex diseases with greater precision. MIPSA technology organizes protein molecules into structured assemblies for better analysis and quantification, increasing sensitivity and accuracy in protein detection, which is beneficial for research and diagnostics. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology firm, launched a next-generation antibody profiling platform that employs MIPSA technology for high-throughput, cost-effective analysis of immune responses, with the goal of improving disease understanding and personalizing treatment strategies.
Collaborations and partnerships are strategic trends gaining traction in the next-generation antibody therapeutics market. Such collaborations facilitate innovation, harness complementary expertise, and expedite the development and commercialization of advanced therapies. In December 2023, AbbVie Inc., a US-based pharmaceutical company, collaborated with BigHat Biosciences, a protein therapeutics company, to leverage machine learning (ML) and artificial intelligence (AI) for discovering therapeutic antibodies. This collaboration aims to advance the development of next-generation therapeutic antibodies through BigHat Biosciences' Milliner platform, combining ML technologies with a high-speed wet lab for antibody design and selection.
In October 2022, AbbVie, a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based developer of therapeutic monoclonal antibodies. This strategic acquisition enhances AbbVie's antibody research initiatives, expands its immunology portfolio, and strengthens its position in Oxford's thriving bioscience sector.
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the next-generation antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The next-generation antibody therapeutics market consists of revenues earned by entities by providing services such as antibody engineering, antibody manufacturing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation antibody therapeutics market also includes sales of immune checkpoint inhibitors, antibody-targeted nanoparticles, and antibody-mimetic proteins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Next-Generation Antibody Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on next-generation antibody therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for next-generation antibody therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation antibody therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Types Of Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Biospecific Antibodies; Antibody-Drug Conjugates; Other Types
- 2) By Therapeutic Area: Oncology; Autoimmune Diseases; Infectious Diseases; Neurodegenerative Disorders; Other Therapeutic Areas
- 3) By End-User: Hospitals And Clinics; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
- Subsegments:
- 1) By Monoclonal Antibodies: IgG Monoclonal Antibodies; IgM Monoclonal Antibodies
- 2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies; Hybridoma-Derived Polyclonal Antibodies
- 3) By Bispecific Antibodies: Dual-Targeting Antibodies; Single-Chain Variable Fragment (scFv) Antibodies
- 4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs; Payload Types
- 5) By Other Types: Nanobodies; Engineered Antibodies
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Amgen Inc.; Moderna Inc.; BioNTech SE; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Celgene Corporation; Lonza Group AG; Catalent Inc.; Genentech Inc.; Kyowa Hakko Kirin Co. Ltd.; Samsung Biologics; WuXi Biologics; Seagen Inc.; Seattle Genetics Inc.; Xencor Inc.; ImmunoGen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Next-Generation Antibody Therapeutics Market Characteristics
3. Next-Generation Antibody Therapeutics Market Trends And Strategies
4. Next-Generation Antibody Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Next-Generation Antibody Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Next-Generation Antibody Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Next-Generation Antibody Therapeutics Market Growth Rate Analysis
- 5.4. Global Next-Generation Antibody Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Next-Generation Antibody Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Next-Generation Antibody Therapeutics Total Addressable Market (TAM)
6. Next-Generation Antibody Therapeutics Market Segmentation
- 6.1. Global Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Monoclonal Antibodies
- Polyclonal Antibodies
- Biospecific Antibodies
- Antibody-Drug Conjugates
- Other Types
- 6.2. Global Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurodegenerative Disorders
- Other Therapeutic Areas
- 6.3. Global Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals And Clinics
- Research Institutes
- Pharmaceutical And Biotechnology Companies
- Other End-Users
- 6.4. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- IgG Monoclonal Antibodies
- IgM Monoclonal Antibodies
- 6.5. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Serum-Derived Polyclonal Antibodies
- Hybridoma-Derived Polyclonal Antibodies
- 6.6. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dual-Targeting Antibodies
- Single-Chain Variable Fragment (scFv) Antibodies
- 6.7. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADCs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Targeted ADCs
- Payload Types
- 6.8. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nanobodies
- Engineered Antibodies
7. Next-Generation Antibody Therapeutics Market Regional And Country Analysis
- 7.1. Global Next-Generation Antibody Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Next-Generation Antibody Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Next-Generation Antibody Therapeutics Market
- 8.1. Asia-Pacific Next-Generation Antibody Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Next-Generation Antibody Therapeutics Market
- 9.1. China Next-Generation Antibody Therapeutics Market Overview
- 9.2. China Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Next-Generation Antibody Therapeutics Market
- 10.1. India Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Next-Generation Antibody Therapeutics Market
- 11.1. Japan Next-Generation Antibody Therapeutics Market Overview
- 11.2. Japan Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Next-Generation Antibody Therapeutics Market
- 12.1. Australia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Next-Generation Antibody Therapeutics Market
- 13.1. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Next-Generation Antibody Therapeutics Market
- 14.1. South Korea Next-Generation Antibody Therapeutics Market Overview
- 14.2. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Next-Generation Antibody Therapeutics Market
- 15.1. Western Europe Next-Generation Antibody Therapeutics Market Overview
- 15.2. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Next-Generation Antibody Therapeutics Market
- 16.1. UK Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Next-Generation Antibody Therapeutics Market
- 17.1. Germany Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Next-Generation Antibody Therapeutics Market
- 18.1. France Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Next-Generation Antibody Therapeutics Market
- 19.1. Italy Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Next-Generation Antibody Therapeutics Market
- 20.1. Spain Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Next-Generation Antibody Therapeutics Market
- 21.1. Eastern Europe Next-Generation Antibody Therapeutics Market Overview
- 21.2. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Next-Generation Antibody Therapeutics Market
- 22.1. Russia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Next-Generation Antibody Therapeutics Market
- 23.1. North America Next-Generation Antibody Therapeutics Market Overview
- 23.2. North America Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Next-Generation Antibody Therapeutics Market
- 24.1. USA Next-Generation Antibody Therapeutics Market Overview
- 24.2. USA Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Next-Generation Antibody Therapeutics Market
- 25.1. Canada Next-Generation Antibody Therapeutics Market Overview
- 25.2. Canada Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Next-Generation Antibody Therapeutics Market
- 26.1. South America Next-Generation Antibody Therapeutics Market Overview
- 26.2. South America Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Next-Generation Antibody Therapeutics Market
- 27.1. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Next-Generation Antibody Therapeutics Market
- 28.1. Middle East Next-Generation Antibody Therapeutics Market Overview
- 28.2. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Next-Generation Antibody Therapeutics Market
- 29.1. Africa Next-Generation Antibody Therapeutics Market Overview
- 29.2. Africa Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Next-Generation Antibody Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Next-Generation Antibody Therapeutics Market Competitive Landscape
- 30.2. Next-Generation Antibody Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
31. Next-Generation Antibody Therapeutics Market Other Major And Innovative Companies
- 31.1. GlaxoSmithKline plc
- 31.2. Takeda Pharmaceutical Company Limited
- 31.3. Gilead Sciences Inc.
- 31.4. Boehringer Ingelheim International GmbH
- 31.5. Amgen Inc.
- 31.6. Moderna Inc.
- 31.7. BioNTech SE
- 31.8. Regeneron Pharmaceuticals Inc.
- 31.9. Biogen Inc.
- 31.10. Celgene Corporation
- 31.11. Lonza Group AG
- 31.12. Catalent Inc.
- 31.13. Genentech Inc.
- 31.14. Kyowa Hakko Kirin Co. Ltd.
- 31.15. Samsung Biologics
32. Global Next-Generation Antibody Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market
34. Recent Developments In The Next-Generation Antibody Therapeutics Market
35. Next-Generation Antibody Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Next-Generation Antibody Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Next-Generation Antibody Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Next-Generation Antibody Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
